Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG (CRSP) Cash flow


Crispr Therapeutics AG Cash Flow

CRSP's free cash flow for Q1 2023 was $5.74M. For the 2023 fiscal year, CRSP's free cash flow was decreased by $-990.20M and operating cash flow was $8.80M. See a summary of the company’s cash flow.
Cash Flow
Dec 22Dec 21Dec 20Dec 19Dec 18
Operating Cash Flow
$ -351.70M$ -495.74M$ 538.97M$ -238.37M$ 56.68M$ -96.24M
Investing Cash Flow
$ -26.31M$ -258.65M$ -1.04B$ -541.17M$ 1.32M$ -2.77M
Financing Cash Flow
$ 33.35M$ 38.59M$ 250.94M$ 1.02B$ 430.98M$ 315.93M
Cash Flow From Discontinued Operation
Other Cash Adjustment Inside Changein Cash
End Cash Position
$ 1.60B$ 224.06M$ 939.94M$ 1.19B$ 948.81M$ 459.81M
Income Tax Paid Supplemental Data
Interest Paid Supplemental Data
Issuance Of Capital Stock
$ 970.00K$ 970.00K$ 213.27M$ 982.29M$ 415.02M$ 307.05M
Issuance Of Debt
-----$ 0.00
Repayment Of Debt
Free Cash Flow
$ -376.60M$ -532.93M$ 457.27M$ -256.72M$ 49.99M$ -99.01M
Domestic Sales
Foreign Sales
Currency in USD

Crispr Therapeutics AG Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis